Labcorp Holdings

LH: Share Repurchases And Alzheimer’s Test Launch Will Drive Profits Ahead

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Aug 24

Updated

14 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

10.1%

7D

1.6%

Loading

1Y

10.1%

7D

1.6%

You can edit this narrative until Nov 15 6:10 PM. Then, changes will post as Updates.

Author's Valuation

US$300.1211.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 14 Nov 25

Fair value Increased 0.33%

LH: Share Repurchases And Expanded Alzheimer’s Testing Will Drive Future Upside

Narrative Update: Labcorp Holdings Analyst Price Target Adjustment Analysts have raised their price target for Labcorp Holdings by $1. This change reflects a marginally improved outlook based on updated fair value and company fundamentals.

Shared on 31 Oct 25

Fair value Increased 0.99%

Analysts have modestly raised their price target for Labcorp Holdings from $296.18 to $299.12. They cite solid improvements in projected profit margins, which offset slightly lower top-line growth expectations.

Shared on 17 Oct 25

Fair value Increased 0.52%

Analysts have modestly raised their price target for Labcorp Holdings to $296.18 from $294.65. They cite incremental improvements in revenue growth projections, despite a slight dip in estimated profit margin.

Shared on 03 Oct 25

Fair value Increased 0.30%

Labcorp Holdings' analyst price target has been revised upward from $293.76 to $294.65. This modest increase is attributed by analysts to slight improvements in projected revenue growth and future valuation metrics.

Shared on 07 May 25

Fair value Increased 8.75%

Shared on 30 Apr 25

Fair value Increased 0.093%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 0.40%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 16 Apr 25

Fair value Decreased 1.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.026%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 3.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 0.50%

AnalystConsensusTarget Fair Value

US$300.12

11.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

4.32%

Healthcare Services revenue growth rate

0.22%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$1.38b

Earnings '28

x

21.24x

PE Ratio '28

=

US$29.38b

Market Cap '28

US$29.38b

Market Cap '28

/

80.72m

No. shares '28

=

US$363.92

Share Price '28

US$363.92 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$297.44

Fair Value '25